Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bronchial Asthma

Conditions

Bronchial Asthma

Trial Timeline

Oct 17, 2018 → Mar 31, 2020

About Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT

Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT is a phase 3 stage product being developed by Cipla for Bronchial Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT03394989. Target conditions include Bronchial Asthma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03394989Phase 3Completed

Competing Products

20 competing products in Bronchial Asthma

See all competitors